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Objectives: To explore the influence of treatment package time(TPT) in high-risk oral cavity squamous cell car
cinoma(OCSCC) receiving adjuvant radiotherapy with concurrent chemotherapy(CRT).
Materials and Methods: We queried our multi-institutional OCSCC collaborative database for cases diagnosed
between 2005 and 2015 who underwent surgery followed by adjuvant CRT. All patients had high-risk features:
extranodal extension(ENE) and/or positive surgical margin(PM). TPT was days between surgery to last radio
therapy fraction. Kaplan-Meier curves, log-rank p-values and multivariate analysis(MVA) were used to investi
gate the impact of TPT on overall(OS), disease-free(DFS), locoregional failure-free(LRFS) and distant metastasesfree(DMFS) survival.
Results: We identified 187 cases: median age 58 (range, 24–87 years), males 66%, and ever smokers 69%. ENE
and PM were detected in 85% and 32%, and oral tongue and floor of the mouth constituted 49% and 18%,
respectively. Median radiotherapy and cisplatin doses received were 66 Gy and 200 mg/m2. Overall, median TPT
was 98 (range, 63–162 days). OS was worse for TPT > 90-days (n = 134) than TPT ≤ 90 (n = 53) at two-(65% vs.
71%) and five-years (45% vs. 62%); p = 0.05, with similar results for DFS. No influence on LRFS or DMFS was
noted. More lymph nodes(LN) dissected(P = 0.039), T3-4 disease(P = 0.017), and unplanned reoperations(P =
0.037) occurred with TPT > 90-days. On MVA, TPT in 10-day increments was independently detrimental for OS
(Hazard Ratio: 1.14; 95 %Confidence Interval [1–1.28]; P = 0.043), perineural invasion, age and positive LN (p
< 0.05 for all).

The results of this study were presented in part at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), held in Chicago, IL, from
September 15 to 18, 2019 (Abstract ID 2924).
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Conclusion: In one of the largest multi-institutional cohorts, TPT > 90-days predicted worse OS for high-risk
OCSCC receiving adjuvant CRT. All efforts are needed to optimize perioperative care and baseline conditions
for favorable outcomes.

Introduction

Materials and Methods

Oral cavity cancers constitute a significant challenge, with around
2% of all new cancer cases and 1.8% of total deaths in 2020 worldwide
[1]. In the United States, 35 540 new cases and 6980 deaths are expected
in 2021 [2]. The standard of care for oral cavity squamous cell carci
noma (OCSCC) involves definitive surgical resection followed by adju
vant radiation therapy (RT) with/without concomitant chemotherapy
(CRT) according to patient, surgical and tumor characteristics [3].
According to the combined analysis of two major randomized trials
by Radiation Therapy Oncology Group (RTOG 9501) [4], and European
Organization for Research and Treatment of Cancer (EORTC 22931) [5],
the benefit of the addition of concurrent chemotherapy was predomi
nantly seen in those with positive surgical margins (PM) or extranodal
extension (ENE) or both. OCSCC formed approximately 26% of both
trials’ population [6]. Improved outcomes were maintained at ten years’
follow up of the combined analysis [7].
In patients undergoing surgical staging and receiving post-operative
RT alone, the detrimental impact of prolonging the treatment duration
has been reported. Treatment duration parameters includes interval
from surgery to RT commencement, overall RT duration (first to last day
of RT course) and treatment package time (TPT) which encompasses the
time from surgical resection till the last RT fraction. The National
Comprehensive Cancer Network (NCCN) endorsed the recommendation
to start adjuvant RT within six weeks interval surgery [3]. This guideline
was based primarily upon a meta-analysis of six important trials that
included 851 patients. The authors noted an odds ratio of 2.89 for local
recurrence in patients starting RT beyond six weeks of surgery [8].
Nevertheless, a National Cancer Database (NCDB) study revealed that
55.7% of the included subjects failed to start adjuvant RT within the
preferred six weeks window, and OCSCC constituted a more significant
proportion of them than other subsites [9]. Another study in patients
with locally advanced head and neck cancer noted a 61% noncompliance with the 42-day surgery to RT start cut-off. However, this
delay did not have a prognostic impact on the OCSCC patient subgroup
analysis [10].
Other studies demonstrated detrimental effects for unplanned
treatment breaks during radiation therapy, which extended overall RT
duration [11–13]. This impact became deleterious when restricted to
higher risk cases receiving > 60 Gy [13]. On the other hand, a pro
spective trial failed to show improved locoregional control with accel
erated fractionation for high-risk candidates, except for those who
started RT more than six weeks after surgery [14].
Therefore, the concept of TPT, which includes both the previous time
components, emerged. A multitude of studies depicted a robust influ
ence for TPT on survival endpoints, and accordingly, they proposed a
range of 77–100 days to represent the ideal TPT [14,15–17]. Tribius
et al. and Rosenthal et al. utilized recursive partitioning analysis (RPA)
and determined the optimal TPT to be 87 and 85 days, respectively
[18,19]. Contrarily, other studies refuted the significance of TPT fa
voring other time components [11,12].
Nonetheless, these studies had some limitations: the utilization of old
RT modalities, the inclusion of non-OCSCC cases, and, more impor
tantly, lack or under-representation of patients that received adjuvant
CRT. Therefore, in a multi-institutional setting, we investigated the
impact of TPT on survival endpoints for a homogenous population of
surgically resected high-risk OCSCC, who received adjuvant CRT using
contemporary techniques and modern doses.

Data source and patient selection
We queried our multi-institutional OCSCC collaborative database,
which includes a total of 1282 patients from six different academic in
stitutions, to identify non-metastatic high-risk patients managed by
surgical staging followed by adjuvant CRT between January 31st, 2005
and January 31st, 2015. Approvals were obtained from each of the six
participating institutional review boards before populating the
database.
Covariates (Study Variables)
Data collection included demographics, pathological features and
treatment details (surgery, radiation therapy and chemotherapy) in
addition to follow up, recurrence patterns and survival status at last
follow-up. High-risk patients are defined as having a positive final sur
gical margin (PM), ENE or both. ENE encompassed any evidence for
extracapsular extension of positive lymph nodes (LN) in the final sur
gical pathology report, with no data on the exact extent or any other
details not reported consistently in participating institutions along the
study timeline. Accordingly, we excluded all low/intermediate-risk
cases lacking any of these features, those treated outside the study
date range, and those who did not receive adequate RT (total dose < 50
Gy) and/or concomitant chemotherapy. We also excluded patients
where the TPT was>180 days or dates of therapy were not exactly
determined.
Outcome assessment
TPT was calculated for all included cases as days elapsing between
the date of surgery and the date of last RT fraction. This included
components of time from surgery to initiation of RT and overall RT
duration (first-last RT fraction), that were also calculated. Consequently,
we stratified TPT in 10 days increments (10D-INC). In order to investi
gate the optimal TPT cutoff value, Kaplan-Meier curves were plotted,
and log-rank tests were used to compare survival endpoints across
different cutoff points (90, 100, and 110 days) and in 10D-INCs of TPT.
Endpoints included overall survival (OS) which was calculated from
the date of surgery to the date of death from any cause), disease free
survival (DFS) which was calculated from the date of surgery to the date
of death or first recurrence, locoregional failure free survival (LRFS)
which was calculated from the date of surgery to the date of first
regional/nodal recurrence and distant metastases free survival (DMFS)
which was calculated from the date of surgery to the date of first distant
recurrence.
Statistical analysis
Patient, pathological and treatment characteristics were compared
between TPT groups using Chi-square and Fisher’s Exact tests for cate
gorical (expressed in frequencies and percentages) and Wilcoxon test for
continuous variables (expressed in median and range). A multivariate
analysis (MVA) Cox regression model was developed to identify inde
pendent predictors for survival endpoints. All tests were two-sided and
P-values of 0.05 or less were considered statistically significant. All
statistical analyses were performed using SPSS Statistics V24, IBM
Armonk NJ or R 3.4 (R Foundation Vienna, Austria).
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years (45% vs. 62%); P = 0.049 (Figure 2B); with a median follow up
time of 26.7 (4.7–145.6 months) vs 40.1 (2.8–113.8 months) for both,
respectively. No significant differences were noted for the 100- and 110days’ time-points. Moreover, there was no significant interaction be
tween 10D-INC TPT and both LRFS (HR:1.07 [95% CI:0.91–1.24]; P =
0.397) and DMFS (HR:0.95 [95% CI:0.78–1.15]; P = 0.60). At two- and
five-years LRFS was (71% vs. 76.6% & 65.5% vs. 67.7%); while DMFS
was (79.8% vs. 74.6% & 73.7% vs. 71.9%) for TPT > 90 vs. TPT ≤ 90; P
> 0.05 for all (Figure 2C & 2D).
After we dichotomized our study cohort at TPT 90 days’ time point
(cutoff for OS difference), baseline demographic, and clinicopatholog
ical details were well-balanced between the two resultant groups as
portrayed in Table 1. However, T3-4 tumors were more frequent for TPT
> 90 days (P = 0.017). Both components of TPT (time to RT start and
overall RT duration) were more extended with TPT > 90 days (P <
0.001 for both).

Results
Patient, pathological and treatment characteristics:
We were able to identify a final cohort of 187 cases for high-risk
OCSCC cases managed with surgery followed by adequate doses of
adjuvant CRT between 2005 and 2015 who fit our inclusion criteria as
depicted in Figure.1. The median age was 58 years (range, 24–87 years),
males constituted 65.8%, ever smokers were 68.8% with median packyears of 30 (range, 1–110 pack-years), and 15.4% had a history of
heavy alcohol use. The most common subsite was oral tongue (48.6%; n
= 91) followed by the floor of mouth (17.6%; n = 33). Per the American
Joint Committee on Cancer (AJCC) 8th version, pathological stage IVB
was prevalent (71.4%), followed by stage IVA (24.3%) [20]. ENE and
PM were detected in 68.4% (n = 128) and 16% (n = 30) respectively;
whereas 15.5% (n = 29) had both.
Surgical staging involved bilateral LN dissection in 35.8%, while the
remainder underwent unilateral LN dissection. The median dissected
LNs were 37 (range 9–199) per case with a median positive LN of 2
(range 0–43). Intensity-modulated RT (IMRT) was utilized by 85.8%,
and the rest received conventional three-dimensional RT. Median RT
dose delivered was 66 Gy (50–72 Gy). Cisplatin was used by 75.9% of
the study cohort (median dose: 200 mg/m2 (80–300 mg/m2)), whereas
24.1% received carboplatin or cetuximab according to the decision of
the institutional multidisciplinary tumor board. This decision was owing
to renal disease, hearing problems, or other comorbidities that pre
cluded cisplatin administration.

Multivariate analysis for predictors of survival outcomes
On MVA for OS, 10-D INC (HR:1.14(95% CI:1–1.28); P = 0.043)
remained detrimental after adjusting for lymphovascular invasion (LVI)
and AJCC stage. Perineural invasion (PNI) (P = 0.002), number of
positive LN (P = 0.001), and 10-year increment of age (P = 0.007) were
also independently prognostic for OS. The same factors were also pre
dictive for DFS except for the 10D-INC of TPT, which was rendered only
marginal (HR:1.1 [95% CI:0.98–1.23]; P = 0.096) as shown in Table 2.
For DMFS, PNI was independently prognostic (P = 0.004), and LVSI was
marginal (P = 0.078) in an exploratory model. There was no significant
MVA model for LRFS

TPT groups and survival outcomes
For the entire cohort, the median TPT was 98 days (63–162 days)
split among time to start RT of 51 days (29–109 days) and overall RT
duration of 45 days (33–97 days). Using 10D-INC around median TPT,
only 53 patients (28%) had TPT ≤ 90 days, 57% had TPT ≤ 100, and
79% ≤ 110 days. After a median follow up of 30 months (2.8–145.6
months), each 10D-INC in TPT was associated with worse OS (Hazard
Ratio [HR]:1.18 [ 95% Confidence Interval [CI]:1.06–1.33]; P = 0.003)
and DFS (HR:1.15 [95% CI:1.03–1.28]; P = 0.011), on log-rank test.
Only TPT > 90 vs. TPT ≤ 90 was associated with worse two- and fiveyears’ OS (64.7% vs. 70.5% & 45% vs. 62% respectively; P = 0.05)
(Figure 2A) as well as worse DFS at two (50.9% vs. 61.9%) and five-

Surgical quality metrics analysis
In an attempt to explore the independent impact of TPT on OS rather
than other tumor specific outcomes (LRFS & DMFS) we retrieved
available surgical quality metrics data for our cohort (Table 3). Patients
with TPT > 90 days underwent bilateral LN dissection more frequently
(P = 0.05), with a significantly higher median number of retrieved LN
(38 vs. 35; P = 0.039); and had more unplanned reoperations within 14
days (12.8% vs. 2.1%; P = 0.037) as well.

Figure 1. CONSORT flow chart of inclusion and exclusion criteria reaching the final study cohort of high-risk oral cavity squamous cell carcinoma treated with
surgery followed by adequate radiotherapy with concomitant systemic therapy within 180 days (n = 187) OCSCC, oral cavity squamous cell carcinoma; ENE,
extranodal extension; PM, positive surgical margin; RT, radiation therapy; CRT, chemoradiotherapy.
3
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Figure 2. Kaplan-Meier estimates of survival endpoints for the study cohort (n = 187) dichotomized by treatment package time > 90 days (n = 134) vs. ≤ 90 days (n
= 53) with Log-rank test results: overall survival (A), disease free survival (B), locoregional recurrence free survival (C), and distant-metastasis free survival (D).

Discussion

undergone a subset analysis for OCSCC confirmed a dismal impact on OS
for TPT > 14 weeks (98 days) that was more pronounced in advanced
stages, which parallels our findings, even though only 52% received CRT
[22]. Nonetheless, being NCDB analyses, both studies could not inves
tigate effect of TPT on tumor-specific outcomes (LRFS & DMFS) in
contrast to this study [21,22].
Regarding influence of TPT on RFS, a single institutional study in
which all subjects received CRT showed results like this study, although
OCSCC was only 40% of the cases. TPT cutoff level of 100 days which
was independently prognostic with OS, failed to predict recurrence-free
survival despite being significant in the univariate log-rank test [23].
Similarly, Tribius et al. reported a non-significant association with LRFS
at TPT 100 days (classic cutoff) and also at 87 days (RPA derived) on
MVA, with a positive influence on OS. Nevertheless, OCSCC formed only
28% of the cohort, and CRT was utilized by only 43% with no subanalyses for both [18]. Contrarily, in the final report (20-years follow
up) for a prospective trial for OCSCC, TPT < 85 days was independently
prognostic for better LRFS as well as OS, whereas RT dose-escalation
failed to attain this benefit. However, in this study, none of the highrisk patients had received concurrent chemotherapy [19]. Also, a sin
gle institution study addressing only OCSCC, demonstrated an inde
pendent effect on RFS (HR 2.94 [95% CI:1.20–7.18]) with TPT > 11

It is recommended to start RT within the shortest possible time after
surgery based on an individual evaluation of each patient’s recovery and
healing which is usually within around 4–6 weeks (28–42 days) . An
uninterrupted course of adjuvant head and neck RT should take 40–45
days for a dose of 60–66 Gy. This results in an ideal TPT of 68–87 days.
Our study demonstrated a detrimental impact on overall survival for
each 10 day increase of the TPT in a homogenous group of high-risk
OCSCC managed by adjuvant CRT following definitive surgery in a
multi-institutional database. This deleterious effect was maintained
after adjusting for other confounding factors, albeit no interaction was
detected for locoregional and distant failure. Other classical factors
remained significant.
Tam et al. investigated a similar cohort treated exclusively with
adjuvant CRT and, like the current study, depicted an independent effect
of TPT as a continuous variable on OS with a threshold value of 97 days
beyond which survival worsens. Similar to our study, the median TPT
was around 100 days, and it was even longer for OCSCC subjects. Unlike
our analysis, they did not exclude patients without high-risk features
who received adjuvant CRT and did not perform a sub-analysis for
OCSCC [21]. Another study, with the same median TPT, that has
4
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Table 1
Baseline demographics, clinicopathological characteristics and treatment details
for the study cohort (n = 187) dichotomised by TPT: ≤90 days (n = 53; 28%) vs.
> 90 days (n = 134; 72%).
Characteristic

Median age in years
(range)
Race
Caucasian
African American and others
Male
Smoking status
Current smokers
Prior smokers
Never smoker
Median Smoking index
(pack-years) (range)
Heavy alcohol use
Median charlson
comorbidity Index
(range)
Oral cavity subsite
Oral tongue
Floor of mouth
Alveolus and retromolar
trigone
Other
PET-CT performed for
staging
Histologic grade
Grade 1–2
Grade 3
pT stage (AJCC 8th)
T1-2
T3-4
pN stage (AJCC 8th)
N0-1
N2
N3
Median positive LN (range)
High-risk features
ENE
Positive final surgical margin
Perineural invasion
Lympho-vascular invasion
Median time to start RT
(days) (range)
Median overall RT
duration (days) (range)
Median RT dose delivered
(Gy) (range)
Median total cisplatin dose
(mg/m2) (range)

Table 2
Multivariate analysis Cox regression models results for predictors of survival
endpoints for the entire study cohort (n = 187).
Endpointi

Variable

Response

HR (95% CI)

Pvalue

OSii

TPT

10-D INC

0.043

0.965

Perineural invasion

0.964

LN positive

Present vs.
Absent
Continuous

1.14
(1.00–1.28)
2.05
(1.29–3.25)
1.06
(1.02–1.09)
1.31
(1.07–1.57)
1.11
(0.98–1.23)
1.95
(1.28–2.97)
1.04
(1.01–1.08)
1.21
(1.02–1.42)
3.4
(1.48–7.81)
1.76
(0.94–3.29)

TPT ≤ 90 daysN
¼ 53; 28%

TPT > 90 daysN
¼ 134; 72%

Pvalue

N (%)
54 (24–84)

N (%)
59 (27–87)

43 (81.1%)
10 (18.9%)
53 (67.9%)

108 (80.6%)
26 (19.4%)
134 (64.9%)

19 (38%)
14 (28%)
17 (34%)
25 (2–90)

46 (38.3%)
33 (27.5%)
41 (34.2%)
59 (1–110)

14 (31.1%)
0 (0–8)

29 (27.8%)
1 (0–7)

24 (45.3%)
10 (18.9%)
9 (17%)

67 (50%)
23 (17.2%)
27 (20.1%)

10 (18.8%)
24 (52.2%)

17 (12.7%)
49 (52.9%)

37 (69.9%)
16 (30.2%)

94 (70.1%)
40 (29.9%)

20 (42.6%)
27 (57.4%)

27 (23.5%)
88 (76.5%)

6 (11.3%)
13 (24.5%)
34 (64.2%)
2 (0–14)

14 (10.4%)
23 (17.2%)
97 (72.4%)
3 (0–43)

46 (90.2%)
13 (24.5%)
28 (52.8%)
22 (43.1%)
41 (29–51)

110 (82.7%)
46 (34.6%)
87 (65.9%)
54 (40.9%)
56 (30–109)

43 (33–52)

46 (33–97)

0.001

64 (52–71)

66 (50–70)

0.727

200 (100–300)

200 (80–300)

0.788

Age

0.696
0.998

DFSiii

TPT
Perineural invasion

0.827

Positive LN

0.230
0.343

Age
DMFSiv

Perineural invasion
Lympho-vascular
space invasion

0.167

10 years
increment
10-D INC
Present vs.
Absent
Continuous
10 years
increments
Present vs.
Absent
Present vs.
Absent

0.002
0.001
0.007
0.096
0.002
0.005
0.033
0.004
0.078

Abbreviations: HR, Hazard ratio; CI, confidence interval; OS, overall survival;
TPT, treatment package time; 10D-INC, 10-day increments; DFS, disease free
survival; LN, lymph nodes; DMFS, distant metastases free survival
i
For locoregional failure free survival there was no significant MVA model
ii
Adjusted for lymphovascular space invasion and AJCC T-stage (8th edition)
iii
Adjusted for lymphovascular space invasion
iv
Adjusted for positive lymph node count

0.568
0.981
0.017

Table 3
Surgical details and rates of compliance with quality metrics among study TPT
groups (≤90 days vs. > 90 days)*

0.481

0.071
0.206
0.177
0.100
0.915
<0.001

Metric

TPT ≤ 90 days

TPT > 90 days

Pvalue

Median LN dissected

35 (range
13–86)
12 (24.5%)
45 (84.9%)
2 (4.3%)

38 (range
9–199)
50 (40.3%)
119 (88.8%)
13 (11.9%)

0.039

1 (2.1%)

14 (12.8%)

0.037

Bilateral LN dissection
Number of LN dissected ≥ 18
Unplanned re-admission within
30 days
Unplanned re-operation within
14 days

0.050
0.464
0.136

Abbreviations: TPT, treatment package time; LN, lymph node

CI:1.03–1.05; P < 0.001] [25]. Moreover, unplanned reoperation was
significantly higher with TPT > 90 days, and therefore, the interval to
RT start was prolonged in comparison to TPT ≤ 90 days per our analysis.
Graboyes et al. in another NCDB analysis demonstrated that longer
length of postoperative hospital stay, as well as unplanned 30-day
readmission, predicted longer wait times (from surgery to RT start) on
MVA [9]. It is noteworthy that in another study by our group, authors
demonstrated that failure to comply with two or more of quality metrics
predicted worse outcomes for resected OCSCC. These metrics included
adjuvant RT referral for stages III/IV, more extensive neck dissection,
unplanned reoperations and unplanned readmissions postoperatively
[26]. TPT > 90 days was not associated with any of these except for
higher reoperations within 14 days.
Based on our results, the addition of concurrent chemotherapy did
not seem to overcome the adverse impact of a prolonged TPT on sur
vival. Both days to start RT and overall RT days were significantly longer
in TPT > 90 days. All efforts need to be exerted to optimize baseline
comorbidities, recovery from surgery, and healing issues to secure the
delivery of adequate adjuvant therapy within accepted TPT limits [27].
Meanwhile, more care is needed to anticipate and manage RT related
toxicities and to offer social support in order to avoid CRT long

Abbreviations: TPT, treatment package time; PET-CT, positron emission
tomography-computed tomography; pT, pathological Tumor stage; AJCC 8th,
American Joint Committee on Cancer 8th edition; pN, pathological Nodal stage;
LN, lymph node; ENE, extranodal extension; RT, radiation therapy; Gy, gray

weeks, with only 49.2% receiving CRT [24].
One of the salient features of this study is that we focused only on
high-risk cases with PM and/or ENE, which resulted in a predominance
of Stage IV cases (95.7%) per AJCC 8th version. This was driven mostly
by ENE which is a surrogate for a higher pathological N stage, and
consequently a higher stage group according to AJCC 8th edition [20].
Besides, the only significant difference between our TPT groups, was
more T3-4 cases with TPT > 90 days, which may have resulted in a more
extensive surgery and consequently to a longer course of post-operative
healing, although we do not have details for this. This matches Guttman
et al. who demonstrated that more advanced stages and readmissions
were associated with significantly longer TPT. Meanwhile, longer TPT
was more accentuated in OCSCC compared to other sites on MVA,
resulting in worse OS by 4% for each week of delay [HR 1.04; 95%
5
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interruptions and minimize TPT. These factors are modifiable and are
best handled by a multidisciplinary team who coordinate to provide
comprehensive care and avoid unnecessary delays or RT interruptions
[28]. In addition to robust postoperative care, optimization of logistics
needs special attention since the receipt of adjuvant IMRT as well as
treatment in high-volume academic centers both were associated with
longer waits beyond the recommended six weeks interval [9].
Importantly, other non-surgically related factors might have partic
ipated in the significant effect of longer TPT on OS which was not
associated with a parallel impact on tumor-specific outcomes (LRFS and
DMFS). Although baseline comorbidities, smoking and alcohol levels
were not different across TPT groups; details of social support, overall
functional status and other components of quality of life throughout
treatment course were not available due to the multi-institutional nature
of this study. In addition, systemic therapy and RT related toxicities
were not captured for the study population. These factors have influence
on both components of TPT (time to RT start and overall RT duration)
and are associated with non-disease specific competing risks of death. It
is noteworthy to state that in this homogenous high-risk population the
risk of early recurrence before starting indicated adjuvant RT should not
be disregarded. In our study 9 patients were excluded because of pro
gression during the receipt of adjuvant therapy. A recent study by Yao
et al. demonstrated early recurrence rate of 35% for surgically resected
OCSCC with any high-risk feature by using PET/CT RT planning [29].
Although postoperative PET/CT is not yet a standard of care, masked
early recurrences may be a strong confounding factor to the effect of TPT
on tumor related events.
This study had some significant limitations that need to be high
lighted, including the selection and reporting bias due to the retro
spective nature. Although we had ten years’ data of 6 academic
institutes, we ended up with 187 candidates who fit our strict inclusion
criteria. This tight selection prevented us from running subgroup ana
lyses based on OCSCC subsite bearing in mind diverse pathogenesis and
patients characteristics. Besides, the exact causes of unplanned RT
breaks and failure patterns were not complete for all cases. Again, due to
limited numbers, we were not able to run a subset analysis comparing
outcomes for cisplatin vs. concomitant cetuximab (10%) or carboplatin
(14%) which were prescribed based on contraindications to cisplatin.
Additionally, around 30% (n = 136) of our database high-risk pop
ulation did not receive the planned concurrent chemotherapy, and
another nine cases progressed while on CRT. In a recent French feasi
bility study, only 57.5% were able to complete the indicated course of
CRT, and around 32% failed to receive the 3rd concomitant cisplatin
dose [30]. Besides, 24.1% of the included cases received carboplatin or
cetuximab, which are less effective. This was highlighted in a study that
analyzed the patterns of utilization of chemotherapy among elderly
cases (>70 years). Even though the benefit of CRT was maintained, only
42% of high-risk elderly patients received the indicated concurrent
chemotherapy [31]. Upcoming trials incorporating more tolerable tar
geted agents and/or immunotherapy in the care of high-risk OCSCC
need to recruit this elderly population. We hope results of these trials
such as RTOG 1216 (NCT01810913) and the EORTC DUTRELASCO
(NCT03784066) fill the gap and improve outcomes in high-risk patients
who cannot tolerate full dose cisplatin.

general health condition throughout the treatment course and minimize
toxicities to initiate adjuvant treatment as early as possible with minimal
breaks.
Declaration of Competing Interest
The authors declare the following financial interests/personal re
lationships which may be considered as potential competing interests:
[Farzan Siddiqui reports Honoraria for lectures and travel reimburse
ment from Varian Medical Systems (unrelated to current work); Medical
advisory board from Varian Noona. Jimmy J. Caudell reports COI from
Varian Medical Systems (outside submitted work).The rest declare no
conflict of interest].
Acknowledgements
None.
Role of funding source
No specific funding was disclosed.
Status
New submission. This work has not been previously published in any
language anywhere and is not under simultaneous consideration or in
press by another journal
References
[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
[2] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin.
2021;71(1):7–33. https://doi.org/10.3322/caac.21654. Epub 2021 Jan 12 PMID:
33433946.
[3] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in
oncology: head and neck cancer Version 3.2021. Available from: https://www.
nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf [Accessed On: 22
October, 2021].
[4] Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al.
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamouscell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–44.
https://doi.org/10.1056/NEJMoa032646.
[5] Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre J-L, Greiner RH, et al.
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